Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn�s disease: The extrapolation concept.
Abstract
We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn's disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main topics, given the great opportunity to save resources that can be invested in innovative drugs and the ethical problems that non-medical switching can...
Paper Details
Title
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn�s disease: The extrapolation concept.
Published Date
Jan 1, 2020
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History